According to the latest report by IMARC Group, titled "Spine Biologics Market Report by Product (Spinal Allografts, Bone Graft Substitutes, Cell Based Matrix), Surgery Type (Open Spine Surgery, Minimally Invasive Spine Surgery), End User (Hospitals, Ambulatory Care Centers, Spinal Surgery Centers, Orthopedic Clinics, and Others), and Region 2025-2033," the global spine biologics market reached a value of USD 2.14 Billion in 2024. Spine biologics include varioustools that are generally used for performing spine fusion surgery. They are commonly utilized to treat deformities that occur due to spine trauma, degenerative disorders, and tumors. These tools are usually manufactured using biomaterials, including ceramics, polymers and glasses, that are safe in nature. They aid in promoting bone growth and the healing process while minimizing the disruption of soft tissues. Additionally, spine biologics is considered to be a preferred alternative to spinal orthoses since itreduces the requirement of additional surgical procedures.
Global Spine Biologics Market Trends:
The global market is primarily driven by significant growth in the healthcare sector. Moreover, a considerable increase in investments from private and public agencies across numerous countries to upgrade the existing healthcare infrastructure is creating a positive outlook for the market. Along with this, the rising prevalence of chronic and acute spinal disorders among the masses is providing a boost to the market growth across the globe. In line with this, the increasing geriatric population, which is more susceptible to musculoskeletal ailments, is also propelling the market growth. Furthermore, continual technological advancements and the integration of third-dimensional (3D) imaging, robotics, and artificial intelligence (AI) technologies with spine biologics devices to assist healthcare professionals in performing complex spine surgeries are also positively influencing the market growth. Some of the other factors contributing to the market growth include increasing healthcare expenditure and extensive research and development (R&D) in medical science. Looking forward, the market value is projected to reach USD 2.97 Billion by 2033, expanding at a CAGR of 3.52% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product, Surgery Type, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Arthrex Inc, Alphatec Holdings Inc., Exactech Inc, Johnson & Johnson, Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V. and Zimmer Biomet |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800